Drug Profile

VIP 236

Alternative Names: VIP-236

Latest Information Update: 17 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer
Developer Vincerx Pharma
Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Solid tumours

Highest Development Phases

Phase I Solid tumours

Most Recent Events

17 Oct 2024 VIP 236 is available for licensing as of 07 Oct 2024
10 Oct 2024 Vincerx Pharma completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA and Australia (IV) (NCT05712889)
07 Oct 2024 Efficacy and adverse events data from a phase I trial in Solid tumours released by Vincerx

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com